A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report

Journal of Medical Case Reports

Takashi Nakano²  Tatsuo Suga¹  Toshitaka Maeno¹  Manabu Ueno¹  Daisaku Yoshida²  Hitoshi Ishikawa³  Takeshi Ebara⁴  Noriyuki Okonogi² 

[1] Department of Medicine and Biological Science, Gunma University Graduate School of Medicine, Gunma, Japan;Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan;Department of Radiation Oncology, University of Tsukuba, Ibaraki, Japan;Department of Radiation Oncology, Saitama International Medical Center, Saitama, Japan

关键词: Malignant pleural mesothelioma;    Long-term survivor;    Hyperthermia;    Chemotherapy;   

Others  :  1195176
DOI  :  10.1186/1752-1947-6-427

 received in 2012-05-04, accepted in 2012-11-16,  发布年份 2012

【 摘 要 】

Introduction

Malignant pleural mesothelioma was once a rare finding but its incidence is increasing worldwide, most likely because of widespread exposure to asbestos. Although complete surgical resection is considered the only curative treatment, the results of surgery have shown a median survival time of only one year. In inoperable cases, chemotherapy, radiotherapy, and a combination of both have been considered as palliative therapy. Therefore, outcomes for inoperable cases have been poor. Here, we report the case of a long-term survivor treated with hyperthermia and chemotherapy.

Case presentation

A 61-year-old Japanese man with a performance status of 1 due to chest pain was referred to our hospital. He had a history of asbestos exposure for approximately five years. A computed tomography scan showed diffuse extensive right pleural thickening with small nodular lesions, and video-assisted thoracoscopy revealed tumor invasion of the ipsilateral chest wall muscles. The histopathologic findings were consistent with a diagnosis of malignant pleural mesothelioma (sarcomatoid type). The tumor was diagnosed as being stage cT3N0M0. Our patient refused any invasive therapies including surgery and radiotherapy, and was therefore treated with hyperthermia and systemic chemotherapy with agents such as cisplatin and irinotecan. He underwent three hyperthermia sessions and a single course of chemotherapy without any severe complications. One month after treatment, a follow-up computed tomography scan showed no definitive abnormality in the thoracic space. Our patient has subsequently survived without any evident disease for more than seven years.

Conclusions

The combination of hyperthermia and chemotherapy may be a novel and safe therapeutic option for malignant pleural mesothelioma, and can be considered for patients ineligible for radical treatment. Further clinical studies of the combination of hyperthermia and chemotherapy are needed to confirm the effects of this treatment on malignant pleural mesothelioma.

【 授权许可】

   
2012 Okonogi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Wagner JC, Sleggs CA, Marchand P: Diffuse pleural mesothelioma. Br J Ind Med 1960, 17:260-271.
• [2]Kishimoto T, Ozaki S, Kato K, Nishi H, Genba K: Malignant pleural mesothelioma in parts of Japan in relationship to asbestos exposure. Ind Health 2004, 42:435-439.
• [3]Welker L, Müller M, Holz O, Vollmer E, Magnussen H, Jörres RA: Cytological diagnosis of malignant mesothelioma–improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch 2007, 450:455-461.
• [4]Ishikawa H, Nakayama Y, Sakurai H, Kitamoto Y, Nonaka T, Kiyohara H, Shioya M, Wakatsuki M, Kawamura H, Hasegawa M, Nakano T: Challenge of hyperthermia combined with chemotherapy or chemo-radiotherapy for unresectable intrathotacic malignant tumors: a preliminary result. Jpn J Hyperthermic Oncol 2005, 21:159-169.
• [5]Ebara T, Sakurai H, Wakatsuki M, Nonaka T, Ishikawa H, Kawamura H, Yoshida D, Shioya M, Nakayama Y, Nakano T: Inoperable Pancoast tumors treated with hyperthermia-inclusive multimodality therapies. Lung Cancer 2009, 63:247-250.
• [6]Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, Bains MS, Downey RJ, Ginsberg RJ: A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001, 122:788-795.
• [7]Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW: Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008, 135:620-626.
• [8]Schipper PH, Nichols FC, Thomse KM, Deschamps C, Cassivi SD, Allen MS, Pairolero PC: Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 2008, 85:257-264.
• [9]Batirel HF, Metintas M, Caglar HB, Yildizeli B, Lacin T, Bostanci K, Akgul AG, Evman S, Yuksel M: Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol 2008, 3:499-504.
• [10]de Perrot M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, Roberts H, Tsao MS, Leighl N, Keshavjee S, Johnston MR: Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27:1413-1418.
• [11]Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R, Akhurst T, Rusch VW: Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006, 1:289-295.
• [12]Steele JP, Klabatsa A: Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 2005, 16:345-351.
• [13]Janne PA: Chemotherapy for malignant pleural mesothelioma. Clin Lung Cancer 2003, 5:98-106.
• [14]Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
• [15]Nakano T, Chahinian AP, Shinjo M, Togawa N, Tonomura A, Miyake M, Ninomiya K, Yamamoto T, Higashino K: Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 1999, 85:2375-2384.
• [16]Tsavaris N, Mylonakis N, Karvounis N, Bacoyiannis C, Briasoulis E, Skarlos D, Pavlidis N, Stamatelos G, Kosmidis P: Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer 1994, 11:299-303.
• [17]Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, Serrano J, Pennucci MC, Soresi E, Crippa M: Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 1991, 67:2984-2987.
• [18]Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW: A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002, 87:491-496.
• [19]Dewey WC, Hopwood LE, Sapareto SA, Gerweck LE: Cellular response to combinations of hyperthermia and radiation. Radiology 1977, 123:463-474.
• [20]Suit HD, Gerweck LE: Potential for hyperthermia and radiation therapy. Cancer Res 1979, 39:2290-2298.
• [21]Roizin-Towle L, Pirro JP: The response of human and rodent cells to hyperthermia. Int J Radiat Oncol Biol Phys 1991, 20:751-756.
• [22]Richter K, Haslbeck M, Buchner J: The heat shock response: life on the verge of death. Mol Cell 2010, 40:253-266.
• [23]Roth M, Zhong J, Tamm M, Szilard J: Mesothelioma cells escape heat stress by upregulating Hsp40/Hsp70 expression via mitogen-activated protein kinases. J Biomed Biotechnol 2009, 2009:451084.
• [24]Matsuzaki Y, Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T: Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma. Ann Thorac Cardiovasc Surg 2008, 14:161-165.
• [25]Xia H, Karasawa K, Hanyu N, Chang TC, Okamoto M, Kiguchi Y, Kawakami M, Itazawa T: Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma. Int J Hyperthermia 2006, 22:613-621.